Advances in Alzheimer’s

More clinical evidence is needed to guide decisions on whether to discontinue lecanemab at 18 months in patients with Alzheimer’s disease who are currently receiving it.

Anti-amyloid treatments have transformed Alzheimer’s disease therapeutics, but more work may be needed before they are clinically useful for most patients with the disease.

Blood-based biomarkers are a useful tool for stratifying an individual’s risk for Alzheimer’s disease in the early stages of cognitive decline, but do they actually diagnose AD in the truest sense?

Biomarkers could be useful for helping patients with subjective cognitive decline better understand the pathology associated with their symptoms, but consensus suggests that more work is needed before they are tested in every patient.

TRAILBLAZER-ALZ 4 trial shows greater and earlier amyloid plaque clearance at 18-months with donanemab versus aducanumab.

Study findings support the superior biomarker potential of p-tau 217 in predicting beta-amyloid positivity and diagnosing Alzheimer’s disease.

Researchers have estimated that the majority of amyloid plaque reduction achieved with donanemab treatment occurs by 64 weeks of treatment, and once off treatment, the median reaccumulation rate in patients remains low.

Disease-modifying effects of lecanemab continue through 24 months in patients with early Alzheimer’s disease, with those at early pathogenetic stage potentially showing the greatest benefit.

Baseline amyloid level is a key factor for predicting amyloid plaque clearance at 24 and 52 weeks of treatment with donanemab.